Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254773 | 0.83 | CES1 (0.65) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL1436249 | 0.83 | CES1 (0.65) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL248294 | 0.82 | TSHR (0.64) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL4399328 | 0.81 | ALDH1A1 (0.63) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL15082296 | 0.81 | CES1 (0.68) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL23037596 | 0.80 | CES1 (0.61) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL514703 | 0.80 | CES1 (0.61) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL306161 | 0.80 | POLB (0.81) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL11455797 | 0.80 | CES1 (0.61) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL402230 | 0.80 | TSHR (0.62) | ALDH1A1CES1CA1CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114136-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | Stealth BioTherapeutics Corp (MC) | 2017-01-11 | — | — | EP | claimed |
| EP-3087093-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2016-11-02 | — | — | EP | claimed |
| WO-2015134096-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2015-09-11 | — | — | WO | claimed |
| WO-2015100376-A1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2015-07-02 | — | — | WO | claimed |
| EP-2240447-A2 | MORPHOLINE DERIVATES AS ANTIOBESITY AGENTS | AstraZeneca AB (Publ) (SE) | 2010-10-20 | — | — | EP | claimed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | claimed |
| EP-2229362-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | AstraZeneca AB (SE) | 2010-09-22 | — | — | EP | claimed |
| EP-2227461-A1 | NEW COMPOUNDS III | AstraZeneca AB (Publ) (SE) | 2010-09-15 | — | — | EP | claimed |
| WO-2010008826-A1 | MODULAR MONOLAYER COATINGS FOR SELECTIVE ATTACHMENT OF NANOPARTICLES TO BIOMOLECULES | PRINCETON UNIVERSITY (US) | 2010-01-21 | — | — | WO | claimed |
| WO-2009071678-A2 | MORPHOLINE DERIVATIVES AS ANTIOBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| WO-2009071658-A1 | PIPERAZINES AS ANTI-OBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| US-11820863-B2 | Fluorosurfactants | SPHERE FLUIDICS LIMITED (GB) | 2023-11-21 | — | — | US | disclosed |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| WO-1998057932-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998019710-A2 | DELIVERY OF NUCLEIC ACID MATERIAL TO TARGET CELLS IN BIOLOGICAL SYSTEMS | SCHACHT ETIENNE HONORE (BE) | 1998-05-14 | — | — | WO | disclosed |
| WO-1998018754-A1 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES, AND COMBINATORIAL LIBRARIES THEREOF | VERSICOR, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0375395-A2 | Derivatives of 3'-and 3\"-0-desmethyl avermectin compounds | MERCK & CO. INC. (US) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | ALDH1A1 4179/4885CES1 887/4885CA1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.